BSX vs OBIO
BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties. OBIO: A clinical-stage biomedical company developing high-impact medical devices through a partnership-enabled business model that shares development risk and rewards with global medical device leaders.
Side-by-side fundamentals
| Metric | BSX | OBIO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $42.04 | $5.73 | |
| Market cap | $60.9B | $344M | |
| P/E as of 2026-10-08 | 17.05 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.27 | n/a | |
| Net margin FY2025, SEC XBRL | +14.4% | -157.4% | BSX higher |
| Gross margin FY2025, SEC XBRL | +69.0% | n/a | |
| Operating margin FY2025, SEC XBRL | +18.0% | -154.7% | BSX higher |
| ROE FY2025, SEC XBRL | +11.8% | -98.4% | BSX higher |
| ROA FY2025, SEC XBRL | +6.6% | -45.9% | BSX higher |
| Debt / equity as of 2026-09-03 | 0.51 | 0.28 | OBIO lower |
| Revenue growth (YoY) as of 2026-09-03 | +13.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +111.6% | OBIO higher |
| Dividend yield | n/a | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.57 | 1.49 | |
| 1-year return as of 2026-10-08 close | -56.6% | +97.6% | OBIO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.